# A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease

> **NCT05662241** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Zenas BioPharma (USA), LLC** · enrollment: 194 (actual)

## Conditions studied

- IgG4 Related Disease

## Interventions

- **DRUG:** Obexelimab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05662241
- **Lead sponsor:** Zenas BioPharma (USA), LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-01-09
- **Primary completion:** 2025-11-13
- **Final completion:** 2029-02-15
- **Target enrollment:** 194 (ACTUAL)
- **Last updated:** 2026-02-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05662241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05662241, "A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05662241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*